EGFR and glioblastoma: IDHwt hLGG is characterised by pTERT mutation, and/or the gain of chromosome 7 combined with the loss of chromosome 10 (7+/10−) and/or epidermal growth factor receptor (EGFR) amplification [17], and so, according to the 2021 WHO Classification of Tumors of the Central Nervous System, IDHwt hLGG should be classified as glioblastoma.